General Drug References
Alvarez J, de Gier H, Mercier-Guyon C, Verstraete A; ICADTS Working Group. Categorization System for Medicinal Drugs Affecting Driving Performance. Oslo, Norway: International Council on Alcohol, Drugs and Traffic Safety; June 26, 2007. See www.icadts.nl/reports/medicinaldrugs1.pdf.
Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 8th ed. Foster City, Calif: Biomedical Publications; 2008.
Designated Aviation Medical Examiner’s Handbook. Version 3.6. Civil Aviation Safety Authority, Australian Government; November 2008. See www.casa.gov.au/manuals/regulate/dame/index.htm.
International Council on Alcohol, Drugs and Traffic Safety. ICADTS Drug List. Oslo, Norway; July 2007. See www.icadts.nl/reports/medicinaldrugs2.pdf.
National Fire Protection Association. 1582 Standard on Comprehensive Occupational Medical Program for Fire Departments. Quincy, Mass; 2007.
PDR.net web site – www.pdr.net
RxList web site – www.rxlist.com
Safety Recommendation, reference A-00-4 through –6. National Transportation Safety Board. Washington, DC; January 13, 2000. See www.ntsb.gov/recs/letters/2000/a00_4_6.pdf.
References on Warfarin (Coumadin)
Cohen DB, Rinker C, Wilberger JE. Traumatic brain injury in anticoagulated patients. J Trauma. 2006;60(3):553-7.
Dunston MS, Ross D. Ground fighting – assaults on police officers. Calibre Press Street Survival Newsline No 630. Calibre Press. Dallas, Texas; January 2003.
Giordano v. City of New York. 274 F.3d 740, 751 (2d Cir. 2001).
Pamar KA, Rao S, Abu-Zidan FM. Head injuries in warfarinised patients. Singapore Med J. 2006;47(8):676-8.
Pickering v. City of Atlanta. 75 F. Supp. 2d 1374 (N.D. Ga. 1999).
References on Specific Drugs
Couper FJ, Logan BK. Drugs and Human Performance Fact Sheets. National Highway Traffic Safety Administration. Washington, DC; April 2004.
Determining Medical Fitness to Operate Motor Vehicles. 7th ed. Canadian Medical Association. Ottawa, Canada; 2006. See www.cma.ca/index.cfm/ci_id/18223/la_id/1.htm.
Frequently Asked Questions (FAQ) – Medical. Federal Motor Carrier Safety Administration. Washington, DC. See www.fmcsa.dot.gov/about/other/faq/faqs.asp?FAQType=1&FaqQ=&FAQTypeSub=0.
Statement from Administrator John H. Hill. Federal Motor Carrier Safety Administration. Washington, DC. See www.fmcsa.dot.gov/statement-5-23-08.htm.
Vermeeren A, Danjou PE, O’Hanlon JF. Residual effects of evening and middle-of-the-night administration of zaleplon 10, and 20 mg on memory and actual driving performance. Hum Psychopharmacol. 1998;13:S98-108.
Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18(5):297-328.
Vermeeren A, Riedel WJ, van Boxtel MP, Darwish M, Paty I, Patat A. Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. Sleep. 2002;25(2):224-31.